Spektus Pharma (Spektus), a Canadian specialty pharmaceutical company and GEBRO Holding GmbH (GEBRO), an Austrian pharmaceutical company, have entered into a strategic global commercialisation partnership for ActraFlex, a novel twice-daily extended-release formulation of tramadol and paracetamol for pain management.

ActraFlex combines Spektus' patented AmyloFlex drug-delivery platform with GEBRO's established Diliban tramadol/paracetamol product. The formulation has been developed to provide sustained drug release and a convenient twice-daily dosing profile for patients requiring pain management.

Under the agreement, GEBRO will oversee commercialisation and supply across Europe and selected Rest of World (RoW) markets, with Spain serving as the primary market, supported by the established regulatory and commercial presence of Diliban. Spektus will be responsible for commercialisation and supply across North America, South America and selected RoW markets through its network of regional commercialisation partners.

The partnership combines GEBRO's experience and established market presence in pain management with Spektus' proprietary drug-delivery technology and international commercialisation network. Both companies aim to leverage their respective capabilities and geographic reach to introduce ActraFlex across multiple international markets.

Commenting on the partnership, Zarvaan Merchant, CEO of Spektus Pharma, said that the agreement highlights the potential of the company's proprietary AmyloFlex technology to develop differentiated specialty medicines using established products and brands. The company also sees commercial opportunities for ActraFlex across the Americas and selected markets in Africa and Asia, building on GEBRO's established commercialisation of Diliban in Europe.

The agreement establishes a global commercialisation framework under which both companies will lead the regulatory and commercial introduction of ActraFlex within their respective territories. The launches will be supported by a common product platform and a coordinated global strategy. Financial details of the agreement have not been disclosed.